CreativeOne Wealth LLC Buys 6,417 Shares of Johnson & Johnson $JNJ

Key Points

• CreativeOne Wealth LLC increased its stake in Johnson & Johnson by 22.7% during the first quarter, now owning 34,658 shares valued at approximately $5.7 million.
• Johnson & Johnson's quarterly earnings report revealed an EPS of $2.77, surpassing analysts' expectations, with revenues of $23.74 billion reflecting a year-over-year growth of 5.8%.
• The company has declared a quarterly dividend of $1.30 per share, contributing to an annualized dividend yield of 2.9% and a dividend payout ratio of 55.61%.

CreativeOne Wealth LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 22.7% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 34,658 shares of the company's stock after buying an additional 6,417 shares during the period. CreativeOne Wealth LLC's holdings in Johnson & Johnson were worth $5,748,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of JNJ. Nuveen LLC purchased a new stake in Johnson & Johnson in the 1st quarter worth $1,369,188,000. GAMMA Investing LLC increased its stake in Johnson & Johnson by 24,450.4% in the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock worth $1,196,596,000 after buying an additional 7,185,977 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Johnson & Johnson by 26.4% in the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock worth $3,844,580,000 after buying an additional 4,842,582 shares in the last quarter. Janus Henderson Group PLC increased its stake in Johnson & Johnson by 134.5% in the 4th quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company's stock worth $1,149,536,000 after buying an additional 4,559,147 shares in the last quarter. Finally, Pacer Advisors Inc. grew its position in shares of Johnson & Johnson by 1,382.0% during the first quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company's stock valued at $502,509,000 after purchasing an additional 2,825,626 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Down 0.7%

NYSE JNJ traded down $1.29 during trading on Thursday, hitting $175.50. The stock had a trading volume of 6,423,524 shares, compared to its average volume of 8,630,407. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The stock has a market capitalization of $422.67 billion, a price-to-earnings ratio of 18.77, a P/E/G ratio of 2.25 and a beta of 0.41. Johnson & Johnson has a one year low of $140.68 and a one year high of $181.16. The stock has a 50 day simple moving average of $165.45 and a 200 day simple moving average of $159.86.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm's quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the firm earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 3.0%. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on JNJ shares. Leerink Partners lowered Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Guggenheim restated a "neutral" rating and set a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Bank of America raised their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research report on Thursday, July 17th. Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Finally, Morgan Stanley raised their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and an average target price of $176.29.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.